Thursday, September 30, 2010

10 Steps to Clinical Study Startup: Step 2 – How to send requests to investigative sites

Partnerships In Clinical Trials 2011 Media Partner goBalto has teamed up with this blog to bring you weekly perspectives on the clinical trials and outsourcing industry. We are very excited to present you with weekly contributions leading up to next year's event!

10 Steps to Clinical Study Startup: Step 2 – How to send requests to investigative sites
Introduction

Once sponsors have finished generating a short list of investigative sites, the next key activity is to contact the sites to assess whether the site has the required facilities and knowledgeable staff to successfully enroll patients and produce high-quality data for a clinical trial. Communication is typically initiated via email, telephone, or fax and are tracked using spreadsheets. Sounds simple right?

How requests are sent and tracked today

Imagine if a sponsor needs to engage 50 investigative sites to enroll patients for a Phase III trial. The sponsor would need to find the site’s contact information, send an email, fax or call, and then document/record each response received. As it turns out, most sponsors use spreadsheets and email folders to track all replies from the sites. Though some sponsors have developed in-house systems to tackle this activity in study startup, most companies don’t have the resources to build and implement an internal solution to facilitate this process.

The major drawback of using spreadsheets to manage and track responses from sites is the amount of manual work needed to keep them updated. A clinical research assistant/associate or clinical project manager needs to manually update the spreadsheet when responses from sites are received. This is not only very tedious but also leaves room for human error and mistakes.

Also, the follow-up procedure when dealing with sites can be cumbersome and lengthy. Spreadsheets work, however they require a great deal of customization and are not the ideal solution for such an important activity of managing and documenting responses from multiple investigative sites. This is a time-consuming activity and every day saved represents a significant amount of money and helps pharmaceutical companies ultimately deliver medicines to those in need faster. Sponsors need to activate sites as quickly as possible so that they can move on with all the other activities, which we’ll cover in future blog postings, so that they can reach the first-patient-in milestone much more quickly.

Sending requests to investigative sites can happen at any point in the clinical trial, not just the study startup phase. If enrollment for a clinical trial is falling behind and the sponsor needs to recruit sites quickly, the sponsor needs to perform the same steps, which adds even more complexity to the tracking procedures.

Caveat: These tasks and activities are performed in a variety of ways depending on the size of the Sponsor, phase of the trial, CRO involvement, however here we covered the general activities that sponsors perform that are general enough to cut across most organizations regardless of the specifics and details. Note that these activities are not necessarily performed in a step-wise fashion, but can happen in parallel with other tasks and at multiple points during study startup.

We would love to hear about your own experiences contacting and tracking communications with investigative sites. Let us know about the processes that have worked for you!

About the Authors

Allan Valmonte is the Senior Director of Business Development at goBalto and has over 12 years of biopharmaceutical drug development experience. He served as a clinical research consultant for KAI Pharmaceuticals and StemCells, Inc., and held positions in clinical research and development at OXiGENE, Cerexa, and Telik. He has also worked on early, late, and post-approval programs for Integrilin® (Millennium), Vectibix® (Amgen), Lipitor® (Pfizer), and Xolair® (Genentech). Allan holds a B.A. in psychology from California State University, Hayward.

Erik Sam is the Senior Director of Customer Development at goBalto and began his career as an engineer in the Process Research and Development department at Genentech, Inc. There he developed and optimized manufacturing processes in Late Stage Purification for numerous products entering clinical trials. He also ran successful GMP campaigns and collaborations with outside vendors to develop new technologies for the entire biotech industry. Erik holds a B.S. in chemical engineering, with a focus in biotechnology, from the University of California, Berkeley.

About goBalto: goBalto is a small team that creates simple, focused and affordable web based software for the global clinical trial industry. Our products offer drug trial sponsors the easiest possible way to start their clinical studies on the web, which makes them feel better. www.gobalto.com




Tuesday, September 28, 2010

Partnerships Asia Pacific Session Spotlight: Build Strong QC and QA Processes within Your Strategic Collaborations

Each week leading up to Partnerships in Clinical Trials Asia Pacific, we'll be highlighting a session from the upcoming conference. It will take place October 5-7, 2010, in Singapore. For more information, visit our webpage to download the brochure.

Featured Session:
Build Strong QC and QA Processes within Your Strategic Collaborations to Ensure an Effective and Compliant Regional Sourcing Strategy
Speaker: Ying Tang, MD, President of Asia Pacific Operations, RPS, INC, China

About the session:
As biopharmaceutical companies develop various sourcing strategy to support the Asia-Pac region, it is clear that there is an increasing level of scrutiny by regulatory agencies on sponsors, providers and investigative sites regarding obligations to ensure adequate oversight and compliance of clinical trials. Regardless of the outsourcing model utilized, the Sponsor retains the ultimate obligation to ensure effective oversight of all internal and external activities related to the conduct of their clinical trial programs. Without an effective quality management process, the potential for good clinical practice (GCP) breaches that impact new drug approvals will continue to exist. This session will examine both a full-service and integrated (embedded) sourcing partnership.

The panel will address the following key elements:
• The key drivers of increasing regulatory oversight and scrutiny in Asia-Pac
• Application of Various QC and QA processes in different outsourced operating models ranging from integrated to full-service models
• Risk management strategies and degrees of sponsor oversight ranging from direct oversight to limited transfer of obligations to full transfer of obligations
• Interdependencies between Training, QC and QA processes
• Continuous improvement methodologies including application of quality KPIs,
error detection and prevention strategies, and audit preparedness and performance strategies





Key Drivers for the Biosimilar Market

1. The global biologics market, which saw a 21% compound annual growth rate between 2003 and 2008, has slowed to 8% but revenue will increase from $110 billion in 2008 to $165 billion in 2013 due largely to rapid growth in monoclonal antibodies.

2. The $20 billion bio- production market is growing at a 7% compound annual growth rate and will likely pass the $25 billion market within three years.

3. A significant number of high-value biologics will lose patent protection starting in 20l2. By 20l3, the value of off patent biologic drugs will exceed $20 billion. or almost 13% of the overall market for biologics.

4. By 2017, biologic therapies with total revenue of $37 billion will have lost patient protection suggesting considerable opportunity for bio similars.

5. Monoclonal antibodies are the fastest growing sub segment of biologics with a 13% compound annual growth rate. The segment will be valued at more than $60 billion by 20l3. Vaccines and cell therapies are a few years away from their peak growth. The vaccines segment valued at $17.5 billion in 2008. is experiencing 9% annual growth which could accelerate due to an increase in R&D investment and an expansion into new indications such as oncology.

6. Innovator drug companies, contract manufacturers and generic drug producers are taking action to add the capacity and scientific expertise needed to play in the bio similars market.

7. Potential hurdles include complex and costly manufacturing technologies; heavy competition; stringent regulatory guidelines in Europe, Middle East, and Africa and the still uncertain regulatory framework in the United States.

Source: http://blogs.veedacr.com/Lists/Posts/Post.aspx?ID=340






Monday, September 27, 2010

Who You Can Meet at Partnerships in Clinical Trials Asia Pacific in Singapore Next Week?

With the #1 clinical development and outsourcing event taking place in next week in Singapore, we to make sure you register before it’s too late!

Partnerships in Clinical Trials Asia Pacific brings you face to face with global and regional partners to improve relationships, streamline operations and drive strategy and results for your next trial at an industry gathering that you cannot afford to miss!

Over 100 leading clinical development and outsourcing executives registered to attend representing Singapore, Malaysia, Indonesia, Thailand and more!

The companies already registered include:

Allergan, Anhvita Biopharma Consulting, Armenti Consulting, Acent Pharma Solutions, Astrazeneca, Atyr Pharma, BMS, Boehringer Ingelheim, Chiltern, Clinigene International, CMIC, Cook Medical, CRF Health, DHL Express, Eisai Clinical Research, Eli Lilly, Family Health International, Genzyme, Gruenthal, Human Genome Sciences, INC Research, Jansen Pharmaceuticals, Jiangsu Hengrui Medicine, Johnson & Johnson, Lundbeck, ManipalaAcunova, Marken, Mebiopharm, Merck, Metabolex, MSD Pharmaceuticals, Novartis, Otsuka Pharmaceuticals, Pangu Biopharma, Parexel, Pfizer China R&D Center, Phoenix Pharma Central Services, PRA International, PRTM, Ranbaxy Laboratories, RPS, Sanofi Aventis, Semler Research Centre, Super Religare Laboratories, Takeda Clinical Research, Transperfect Translations, United Biosource Corporation, Vanthys Pharmaceutical Development, Wockhardt.





Friday, September 24, 2010

GSK chooses CROs

GlaxoSmithKline recently announced that their new strategic partners will be Paraxel and PPD. According to Outsourcing Pharma, these two will provide them with a variety of clinical development in addition to trial services. They've chosen to go with these two providers because it will allow them to work more efficiently.

Do you think this is the continuing of a new trend? Will other Pharma companies reduce the amount of partners they work with in order to streamline their services?




Thursday, September 23, 2010

52 Perspectives: “India’s increasingly important role in clinical research

Partnerships In Clinical Trials 2011 Media Partner goBalto has teamed up with this blog to bring you weekly perspectives on the clinical trials and outsourcing industry. We are very excited to present you with weekly contributions leading up to next year's event!

52 Perspectives: “India’s increasingly important role in clinical research”

Jae Chung
This contribution to ’52 Perspectives’ comes to us from Sanjay Gupta, Director of Clinical Operations at Catalyst Clinical Services Pvt. Ltd. Mr. Gupta having more than 11 years of experience in clinical research and has conducted and supervised over 80 clinical trials across a wide range of therapeutic areas. He has presented his research work in various International Journals and Conferences including ASCO and has authored 6 books on clinical research.

India: an emerging location for the conduct of global clinical trials

A nation with more than 1000 million people, India has the second largest population in the world. It is a sovereign, secular, democratic republic consisting of 28 states, 7 union territories and 593 districts. It has the world’s twelfth largest economy at market exchange rates and the fourth largest economy in purchasing power. With an average annual GDP growth rate of 5.8% for the past two decades, its economy is among then fastest growing economies in the world.

Internationally, India became a member of the World Trade Organization (WTO) in 1995 and agreed to adhere to the product patent regime from 2005. Being a signatory to the WTO agreements, India is being looked upon as a favorable destination for the conduct of global clinical trials. India clearly provides an opportunity in terms of availability of large patient populations, highly educated talent, a wide spectrum of disease, lower costs of operations, English speaking population and a favorable economic and intellectual property environment.

India’s performance in Clinical trials

Data suggests a 50-60% cost saving associated with conducting clinical trials in India compared to the same clinical trials being conducted in US or Western Europe. This is evident by the steadily increasing number of global studies in India over the past few years. With major pharmaceutical/biotech companies and CROs establishing their presence in India, the country is projected to conduct nearly 5% of the global clinical trials in next 5 years. An estimate of the total market for conducting clinical trials either directly or through Contract Research Organizations (CROs) in India till 2010 is projected at US$ 2 billion by major pharmaceutical companies.

Data from the site ClinicalTrials.gov enlists a total number of 1035 clinical studies for India (till July 2009) with 413 studies in the enrollment phase. Of the 1035, studies, 53% are Phase-III trials, 24% are phase-II trials and 6% are phase-I trials.

India is estimated to have more than 3000 GCP compliant investigator sites and 20,000+ GCP trained clinical research professionals. Recent amendment in clinical trial regulation has abolished the phase lag, allowing global clinical trials (phase-II, phase-III) to be conducted at parallel phase in India. A two-tier approval process is followed in India requiring the trial proposals to be approved by the IRBs at the institutional level in addition to the approval by the Drug’s Controller General of India at the country level.

Conclusion

The foundation of knowledge-based industries in India was laid down by the Information Technology industry and clinical research is fast following the footsteps to become the next sunrise industry. Indian Investigators and clinical research professionals have already demonstrated their medical and scientific competence by participating in several global registration trials as well as by publishing their research work in peer-reviewed scientific medical Journals of repute. Soon, Indian clinical research capabilities will become part of clinical development programs across the globe.




About goBalto: goBalto is a small team that creates simple, focused and affordable web based software for the global clinical trial industry. Our products offer drug trial sponsors the easiest possible way to start their clinical studies on the web, which makes them feel better. www.gobalto.com




Wednesday, September 22, 2010

Partnerships Asia Pacific Session Spotlight: Open Innovation in Asia: Why APAC is More than Just a Destination for Outsourcing

Each week leading up to Partnerships in Clinical Trials Asia Pacific, we'll be highlighting a session from the upcoming conference. It will take place October 5-7, 2010, in Singapore. For more information, visit our webpage to download the brochure.

Featured Session:
Open Innovation in Asia: Why APAC is More than Just a Destination
for Outsourcing
Speaker:James Garner, Vice President & General Manager, TAKEDA CLINICAL RESEARCH, Singapore

About the session:
services, but the true value of the region is far more strategic and apparent. There is also a growing trend in collaboration among sponsors in Asia to leverage synergies, expertise and resources to expedite understanding of diseases in various therapeutic areas. This session highlights innovations and opportunities currently being explored in the region, what they mean for the future of R&D, changing business models globally, and the potential impact on strategic clinical partnerships.

• A look forward – what’s the future of collaboration in R&D?
• Asia - the shift from a cost saving tactic to strategic imperative
• How is the changing R&D model going to impact the CRO market?





Tuesday, September 21, 2010

Answers: CROs Market Quiz

A few weeks back, Partnerships Guest Blogger Corrected answers appear in red.

1. Which is the larger deal? Please mention approx deal size in billions.
• The Abbot-NCH takeover
• the Daichi-Ranbaxy Takeover

2. How many NME’s have been approved by the FDA in 2009?
• 30
• 27
• 29
• 32

3. How many Clinical trials are registered at the Indian Clinical Trial registry till date?
• 800
• 950
• 1000
• 1193

4. Which is the recent guidance published on the DCGI website which could act as a major barrier to BA BE studies?
• Change in Format of Ethics committee submission
• Change in Format of medical devices
• Change in timelines for submission
• CoE for export

5. Which is the recent Guidance ( august 2010 ) which applies to those clinical trials under moderate or severe published on the DCGI website:
• Anti hypertensive drugs
• Diabetes drugs
• Cancer trials
• Medical Device trials

6. How many years has Indian Pharma spent in Active R &D?
• 10
• 12
• 14
• 16

7. Which is the Indian company which has entered into a licensing deal for its 41 generic drug products with Pfizer?
• Ranbaxy
• Orchid
• Cipla
• Intas


8. Which is the Indian company which has entered into a licensing deal with MNC, Astra for generic drug products?
• Intas
• Nicholas Piramal
• Abbot
• Torrent

9. Which is the Indian Life science company which has r been issued a warning letter on its antibiotic products in May 2010?
• Cipla
• Ranbaxy
• Claris
• Core Pharma

10. Which of the following companies are into CT supply Outsourcing business in Ahmedabad:
• Synchron
• Lambda
• Thermofisher
• None of the above

11. Which is the NYSE listed CRO which has recently expanded operations in India?
• Parexel
• PPD
• CRV
• Kendle

12. Which is the Indian Pharma Company which has declared its IPO plans of greater than 500crs?
• Glenmark
• Glenmark Generics
• Intas
• Venus Remedies
_____________________________________________________________________
Q & A- Direct questions:

13. Which is the drug and the company which has been warned by the FDA to withdraw their product on account of safety issues in the last 6 months?
Avandia ( Rosiglitazone) by Glaxo

14. Which Global CRO came into limelight after their Phase I trial for an mAB brought 6 volunteers to serious ADR’s?
Parexel in 2006

15. Also name the Hospital and countries involved in the trial. What is the code name of the molecule involved in the trial?
Northwick Park Hospital, UK & Germany, TGN1412

16. Which is the Indian CRO which faced heavy penalties when a volunteer expired during felodipine trial last year?
GVK Biosciences

17. Which company came under the DCGI scanner for vaccine trial on neonates AIMMS hospital on informed consent issues? Also this resulted in the death of one of the infants as well. Name the CRO Involved.
Wyeth, GVK BIO

18. Which Canadian CRO has recently merged with an Indian CRO? Name the PE involved in the deal.
Lambda took over Bioavail Contract research in Canada; Avendus Capital

19. Who is the president of the OPPI? When was the OPPI established?
Organisation of Pharmaceutical producers of India president is Mr Ranjit Sahni of Novartis; 1965

20. Which the only cancer vaccine approved in 2010? What as the company’s name? What is the indication for the vaccine?
Provenge by Dendreon; Prostrate Cancer




Friday, September 17, 2010

Outsourcing to Asia Pacific

To gear up for Partnerships in Clinical Trials Asia Pacific, Simon Britton, Vice President, Clinical Development, PPD, shared this presentation at Partnerships in Clinical Trials Asia Pacific 2009.

Click here to visit the presentation.




Thursday, September 16, 2010

10 Steps to Clinical Study Startup: Step 1 – How to identify qualified sites

Partnerships In Clinical Trials 2011 Media Partner Go Balto has teamed up with this blog to bring you weekly perspectives on the clinical trials and outsourcing industry. We are very excited to present you with weekly contributions leading up to next year's event!

Jae Chung
This is the first installment of our ongoing series on 10 steps to Clinical Study Start Up. We hope you enjoy it. And of course feedback/comments/thoughts are welcome!

Introduction

The first key activity for sponsors when starting up a clinical study is identifying potential investigative sites. Recruiting quality investigators and investigative sites is critical to the overall endgame for a sponsor because this activity directly correlates to quick subject enrollment, high-quality data and subject retention for any clinical study. Most describe this important activity as labor intensive and time-consuming.

We’ve outlined 4 common methods below that Sponsors use to identify investigative sites and commented upon their effectiveness along with some drawbacks.

1. Internal Databases

It’s no surprise that sponsors already have internal databases of sites that they’ve worked with in the past. The advantages of utilizing an internal database are that it is readily accessible and is pre-populated with sites that the sponsor has worked with before. An internal database helps sponsors maintain relationships with sites that have performed well in the past. Since quality sites are difficult to find, maintaining an internal database helps sponsors cultivate long-term relationships with sites they would like to use for future studies.

One major drawback is that the sponsor needs to actively maintain the database. Sponsors have to manually enter new data and track any changes to the database, which gets even more labor intensive as the database becomes larger. While an internal database provides a great starting point for established sponsors, the data is limited and sponsors often need to expand their list of investigative sites for a new clinical study. Internal databases are generally not comprehensive enough to support larger studies and often don’t reflect current data. We are also observing a trend towards an increasing number of sites located in emerging regions, making it harder to gain transparency on who’s good or bad. According to a recent Center Watch study, more 25% of investigators are “first timers” – juggling their own practice, resulting in high turnover is high and poor performance. Staying up to date on qualified investigators is challenging.

2. Contact your friendly neighborhood CRO or SMO

Engaging a Clinical Research Organization (“CRO”) or (“SMO”) as a development partner is a common industry practice for sponsors when starting up clinical studies. CROs can provide a wide range of services to sponsors including site identification as part of the study startup process. CROs that provide site selection services also provide their own list of investigative sites. While several CROs help identify sites, there is an important distinction to consider when evaluating which CRO to partner with. Larger CROs generally have a wide-breadth of expertise and capabilities to handle multiple indications. These larger CROs may be able to service the sponsor, however their list of sites may be out of date since they’re spread across multiple indications. Smaller, niche CROs will more than likely have a more focused and up-to-date list. However, since smaller CROs are niche providers, many of their sites may already be dedicated to other competing studies.

3. Word of mouth

Another effective means of finding sites is identifying a key opinion leader (KOL) in a particular indication. Generally, KOLs are professionals with firsthand knowledge and experience working in a particular indication, whom can be found by scouring scientific publications. Something worth considering when engaging a KOL as an investigative site – just because they’re a KOL doesn’t necessarily mean that they’re a high performing site.

Other investigative sites are also a good resource to tap when needing to identify new sites. Most sites that we’ve come across have acknowledged that they are willing to refer other sites to a sponsor that can accommodate a clinical study.

4. Directories

Sponsors utilize both online and offline directories to identify sites and cast a wide net for site feasibility. Some online directories allow sponsors to search for sites free of charge, while others require a fee. Directories can be large and help sponsors broaden their list of sites, however the drawback is that it’s still difficult to judge the quality of the sites in the directory. Plus, website administrators maintain static directories, therefore Sponsors don’t always get the most current data. While online and offline directories can help sponsors quickly generate a short list of potential investigative sites, sponsors will need to spend more time researching the quality of each new site, a labor intensive and time consuming process. We’ve reviewed some of the online directories sponsors use. You can see read the reviews here.

Closing Thoughts

The methods listed above are by no means comprehensive, but are simply the most common tools we’ve found that sponsors use to identify investigative sites. Sponsors often use a combination of these methods to quickly find the right ones for their clinical study. Identifying sites is one small piece of clinical study startup, and sponsors who invest the time and effort into doing it right will save time and money further down the road.

About the Authors:

Allan Valmonte is the Senior Director of Business Development at goBalto and has over 12 years of biopharmaceutical drug development experience. He served as a clinical research consultant for KAI Pharmaceuticals and StemCells, Inc., and held positions in clinical research and development at OXiGENE, Cerexa, and Telik. He has also worked on early, late, and post-approval programs for Integrilin® (Millennium), Vectibix® (Amgen), Lipitor® (Pfizer), and Xolair® (Genentech). Allan holds a B.A. in psychology from California State University, Hayward.

Erik Sam is the Senior Director of Customer Development at goBalto and began his career as an engineer in the Process Research and Development department at Genentech, Inc. There he developed and optimized manufacturing processes in Late Stage Purification for numerous products entering clinical trials. He also ran successful GMP campaigns and collaborations with outside vendors to develop new technologies for the entire biotech industry. Erik holds a B.S. in chemical engineering, with a focus in biotechnology, from the University of California, Berkeley.

This blog is co-posted with the Go Balto Blog.




Wednesday, September 15, 2010

Partnerships Asia Pacific Session Spotlight: Site Capacity Development and Management: Improving Project Performance in Multi-Nation Trials

Each week leading up to Partnerships in Clinical Trials Asia Pacific, we'll be highlighting a session from the upcoming conference. It will take place October 5-7, 2010, in Singapore. For more information, visit our webpage to download the brochure.

Featured Session:
Site Capacity Development and Management: Improving Project Performance in Multi-Nation/Multi-Centered Trials
Speakers:Ann Wang, Vice President, Clinical Operations and Data Management, HUMAN GENOME SCIENCES, USA
Fidela Ll. Moreno, MD, Vice President, Global Development Operations, Clinical Site Management and Monitoring, ALLERGAN INC, USA

About the session:
Quality of data and practice of medicine top of mind for pharmaceutical executives conducting clinical studies in Asia. There are vast perceived differences regarding the level of exposure of trial experience among investigator sites, CROs and clinical development staff within sponsor companies in Asia. Sponsors must be prepared to address these potential roadblocks and share expertise in following protocol for clinical research.
• Perform a site capacity evaluation and investigator assessment in the region
• Plan for your training and monitoring system to ensure consistent performance
• Ensure clinical trial needs can be met by the site from a staffing, technical and operational perspective
• Juggle internal resource and external support to maintain quality and minimize costs/delays
• Ensure performance and trial quality when faced with fewer experienced investigators and complicated projects






Tuesday, September 14, 2010

Market Overview – ANDA submissions

In the year 2009, a record breaking number of ANDA’s were filed by the by the world’s leading generic drug players. In the year 2009, 100 ANDA’s were filed by the top 10 companies. The top 10 companies account for more than 50% of the total filed ANDA’s. Some of the top Indian companies which have driven the growth of the ANDA market are Wockhardt, Glenmark, Dr. Reddy, Aurobindo and Ranbaxy to name a few. The Indian Pharmaceutical Industry accounts for nearly 32% of the total filed ANDA’s in the year 2009.

Based on these statistics, it can be definitely predicted that growth of the Indian Pharmaceutical companies is likely to achieve its desired milestones. This can only happen f the regulatory laws continue to support the submission rates. The Healthcare reimbursement policies highlighted by the US government clearly favour the use of generic drugs. However, the nature by which the Indian Pharmaceutical companies tackle the “Pay for Delay” / patent litigations, will decide the future of the ANDA submissions.

2009 has been a record low year for new drug applications by the USFDA. Only 27 applications have reached the final stages. It can be clearly seen that safety profiles of newer drugs (i.e. the adverse event profile of the drugs has made companies withdraw their pipelines) are major hurdle in the New Chemical entity market. Existing drugs are now being tested for newer indications. These are also some of the factors which will add to the growth of the generic drug market in the USA.

http://blogs.veedacr.com/Lists/Posts/Post.aspx?ID=338

More at the Veeda Cr Corporate blog at-
http://blogs.veedacr.com/default.aspx





Friday, September 10, 2010

Quintiels Japanese Central Lab receives accreditation

The Quintiles lab in Tokyo, Japan has been accredited by the College of American Pathologists (CAP). It opened in 2008, and joins a largest network in the world of CAP central labs, reports Enhanced Online News.

Thomas Wollman, Senior Vice President, Quintiles Global Central Laboratories, stated:
“CAP accreditation has become the international gold standard for quality, and Quintiles is committed to delivering quality laboratory services that meet complex regulatory requirements in the New Health landscape. Our Tokyo facility is the 10th lab in Quintiles’ network to become CAP certified, validating our efforts to achieve high quality, consistent delivery across every region and every clinical trial.”





Thursday, September 9, 2010

Series Outline: 10 Steps to Clinical Study Start Up

Partnerships In Clinical Trials 2011 Media Partner Go Balto has teamed up with this blog to bring you weekly perspectives on the clinical trials and outsourcing industry. We are very excited to present you with weekly contributions leading up to next year's event!

Author: Jae Chung

Introduction

We all know managing studies are challenging. However, how much thought do you give to improving the startup phase, where much of the critical groundwork is being laid? If you’re like most folks we’ve spoken to, you’ve accepted that the study startup is done through, phone, fax, email and excel spreadsheets. Too complex! Too manual! Too inefficient!

The study startup phase, which includes investigator enrollment and submission of new investigator packages, is a time-consuming component of the clinical study process. The study startup phase is burdened by a manual and heavily paper-based process that involves a legacy IT infrastructure, which is ripe for some optimization.

The Clinical Study Startup Series

This series will focus on this key area of the clinical trial process – study startup – and shows ways on how to optimize each of the steps to gain a significant competitive advantage in new drug product development. We’ve spent the past 6 months, interviewing sponsors, CROs and sites to determine what goes on in the study startup phase and ways the process can be improved.

Here, we’ve summarized the 10 key steps we identified that sponsors take to select sites and activate them for a clinical study. Over the coming weeks we will break down each of these steps and provide you with our key learnings. The goal is to initiate a dialogue with the broader clinical research community on how to improve how things are done.

Coming Soon!

The first part of our series will be published on the Partnerships in Clinical Trials Blog September 16 with tips and suggestions on what you should do when identifying sites.

This blog is co-posted with the GoBalto Blog.




Wednesday, September 8, 2010

Partnerships Asia Pacific Session Spotlight: Optimal Country and Site Selection for Global Clinical Trials

Each week leading up to Partnerships in Clinical Trials Asia Pacific, we'll be highlighting a session from the upcoming conference. It will take place October 5-7, 2010, in Singapore. For more information, visit our webpage to download the brochure.

Featured Session: Optimal Country and Site Selection for Global Clinical Trials
Speakers: Sven Ohlman, Regional Director Clinical Study Operations Asia, ASTRAZENECA, Singapore

In this session, you will:
• Determine where, when and how to expand clinical operations
• Implement global expansion plans successfully
• Create an effective patient recruitment plan





Tuesday, September 7, 2010

More clinical training courses in India courtesy of ICRI and Accenture

Pharma Times Online recently announced the strategic partnership between ICRI and Accenture. Due to the rapidly increasing growth of clinical trials in India, many are worried that it will not have enough man power to sustain the growth in the region. The courses will focus on clinical research and pharmacovigilance. Accenture will help with the training the trainers, curriculum content development, curriculum execution and delivery through periodic guest lectures, certification and re-assessment of trainers to ensure consistent quality, and upgrading the course content in accordance with industry requirements. For completion of the course, students will have to complete 360 hours of study in Basics of Clinical Research, Pharmacology, Pharmacovigilance and Regulations; Case Processing; Aggregate Report; and Risk Management in Pharmacovigilance and Signal Detection.




CROs Market Quiz

Market Quiz

Which is the larger deal? Please mention approx deal size in billions.
The Abbot-NCH takeover
The Daichi-Ranbaxy Takeover

How many NME’s have been approved by the FDA in 2009?
30
27
29
32

How many Clinical trials are registered at the Indian Clinical Trial registry till date?
800
950
1000
1193

Which is the recent guidance published on the DCGI website which could act as a major barrier to BA BE studies?
Change in Format of Ethics committee submission
Change in Format of medical devices
Change in timelines for submission
CoE for export

Which is the recent Guidance ( August 2010 ) which applies to those clinical trials under moderate or severe published on the DCGI website:
Anti hypertensive drugs
Diabetes drugs
Cancer trials
Medical Device trials

How many years has Indian Pharma spent in Active R &D?
10
12
14
16

Which is the Indian company which has entered into a licensing deal for its 41 generic drug products with Pfizer?
Ranbaxy
Orchid
Cipla
Intas

Which is the Indian company which has entered into a licensing deal with MNC, Astra for generic drug products?
Intas
Nicholas Piramal
Abbot
Torrent

Which is the Indian Life science company which has been issued a warning letter on its antibiotic products in May 2010?
Cipla
Ranbaxy
Claris
Core Pharma

Which of the following companies are into CT supply Outsourcing business in Ahmedabad:
Synchron
Lambda
Thermofisher
None of the above

Which is the NYSE listed CRO which has recently expanded operations in India?
Parexel
PPD
CRV
Kendle

Which is the Indian Pharma Company which has declared its IPO plans of greater than 500crs?
Glenmark
Glenmark Generics
Intas
Venus Remedies

Q & A- Direct questions:

Which is the drug and the company which has been warned by the FDA to withdraw their product on account of safety issues in the last 6 months?

Which Global CRO came into limelight after their Phase I trial for an mAB brought 6 volunteers to serious ADR’s?

Also name the Hospital and countries involved in the trial. What is the code name of the molecule involved in the trial?

Which is the Indian CRO which faced heavy penalties when a volunteer expired during felodipine trial last year?

Which company came under the DCGI scanner for vaccine trial on neonates AIMMS hospital on informed consent issues? Also this resulted in the death of one of the infants as well. Name the CRO Involved.

Which Canadian CRO has recently merged with an Indian CRO? Name the PE involved in the deal.

Who is the president of the OPPI? When was the OPPI established?

Which the only cancer vaccine approved in 2010? What as the company’s name? What is the indication for the vaccine?

http://blogs.veedacr.com/Lists/Posts/Post.aspx?ID=337

For answers Please visit the Veeda CR Corporate blog or write to rashmi.pant@veedacr.com.

Alternatively please feel free to contact Partnership in clinical trials at JPereira@IIRUSA.com




Wednesday, September 1, 2010

India's perspective on Outsourcing

Marcel Velterop recently contributed a piece to PharmaTech.com looking at the Indian landscape of CROs and how they've improved and changed over the past 20 years. They've transformed from a low cost region to a location where high quality and compliance have transformed the clinical landscape. Aside from the US, there are now more FDA approved facilities than anywhere else in the world. Velterop looks at how his company, Dr Reddy's Custom Pharmaceutical Services, has taken on this landscape and adjusted to fit the new parameters the growing region is presenting.